Insights

CSL (ASX:CSL) share price higher on US FDA flu vaccine news

CSL’s shares are on form on Wednesday…
The post CSL (ASX:CSL) share price higher on US FDA flu vaccine news appeared first on The Motley Fool Australia. –

The CSL Limited (ASX: CSL) share price is pushing higher on Wednesday morning.

At the time of writing, the biotherapeutics company’s shares are up 1% to $319.78.

Why is the CSL share price rising?

The catalyst for the rise in the CSL share price this morning appears to have been the release of an announcement relating to its Seqirus business.

According to the release, the US Food and Drug Administration (FDA) has granted supplemental approval of a multi-dose vial (MDV) formulation of Audenz. This is the first-ever adjuvanted, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.

Audenz was originally approved by the FDA in a single dose, prefilled syringe (PFS) presentation in 2020.

Management notes that FDA approval of the MDV presentation of Audenz marks an important milestone in Seqirus’ pandemic preparedness efforts in partnership with Biomedical Advanced Research and Development Authority (BARDA).

BARDA is a component of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS).

Under the terms of the public-private partnership, which was established in 2009, Seqirus would position itself to deliver 150 million influenza vaccine doses to the U.S. government to support an influenza pandemic response within six months.

Seqirus executive director Marc Lacey commented:

Producing AUDENZ in multi-dose vials allows for increased speed and efficiency, which is absolutely critical to help protect public health in the case of an influenza pandemic.

According to the CDC, the influenza A(H5N1) virus is highly pathogenic and has high pandemic potential, so it’s critical to be prepared. Seqirus is committed to partnering with key stakeholders to develop adequate and effective influenza pandemic preparedness plans.

What is pandemic influenza?

While similar to seasonal influenza, pandemic influenza is a contagious airborne respiratory disease which is unpredictable in timing and severity and has a higher risk of morbidity and mortality.

This is because there is likely to be little or no pre-existing immunity to the virus in the human population.

CSL notes that four influenza pandemics have occurred over the past century, with the 1918 pandemic being the most severe in recent history and estimated to have killed up to 50 million people worldwide. As such, this makes the work Seqirus is doing extremely important for the global population.

The post CSL (ASX:CSL) share price higher on US FDA flu vaccine news appeared first on The Motley Fool Australia.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

CSL (ASX:CSL) share price struggles despite new government funding

Here’s why these brokers say the CSL (ASX:CSL) share price might be overcooked

2 outstanding blue chip ASX shares to buy this month

Can CSL (ASX:CSL) shares regain their pre-COVID highs above $330?

Why has the CSL (ASX:CSL) share price fallen over $7 in a week?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!